Gene and doxorubicin co-delivery system for targeting therapy of glioma

Biomaterials

Volumn 33, Issue 19, 2012, Pages 4907-4916

  Liu, Shuhuan ^a   Guo, Yubo ^a   Huang, Rongqin ^a   Li, Jianfeng ^a   Huang, Shixian ^a   Kuang, Yuyang ^a   Han, Liang ^a   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cancer targeting; Combination therapy; Doxorubicin; PH sensitive; T7 peptide

Indexed keywords

CANCER-TARGETING; CELLULAR UPTAKE; CHEMOTHERAPEUTIC DRUGS; COMBINATION THERAPY; COMBINATION TREATMENTS; DOXORUBICIN; HYDRAZONE BONDS; IN-VITRO; IN-VIVO; PH SENSITIVE; SYNERGISM EFFECTS; SYNERGISTIC GROWTH; TRANSFERRIN RECEPTORS; TUMOR CELLS;

CHEMOTHERAPY; DISEASES; GENE EXPRESSION; GENE THERAPY; LOADING; PEPTIDES;

TUMORS;

DENDRIMER; DOXORUBICIN; HYDRAZONE DERIVATIVE; TRANSFERRIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CELL TRANSPORT; CHEMICAL BOND; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG UPTAKE; GENE EXPRESSION; GENE THERAPY; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THERAPY EFFECT; ZETA POTENTIAL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; GENE THERAPY; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859817562     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.031     Document Type: Article

References (46)

1. Rainov N.G., Söling A., Heidecke V. Novel therapies for malignant gliomas: a local affair?. Neurosurg Focus 2006, 20:E9.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
3. Kortmann R.D., Jeremic B., Weller M., Plasswilm L., Bamberg M. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 2003, 179:219-232.
4. Rainov N.G., Ren H. Gene therapy for human malignant brain tumors. Cancer J 2003, 9:180-188.
5. Barzon L., Zanusso M., Colombo F., Palù G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther 2006, 13:539-554.
6. Pulkkanen K.J., Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005, 12:585-598.
7. Guan Y.S., Liu Y., He Q., Li X., Yang L., Hu Y., et al. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up. World J Gastroenterol 2011, 17:2143-2149.
8. Prados J., Melguizo C., Rama A.R., Ortiz R., Segura A., Boulaiz H., et al. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2010, 66:69-78.
9. Trabulo S., Cardoso A.M., Santos-Ferreira T., Cardoso A.L., Simões S., Pedroso de Lima M.C. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharmacol 2011, 8:1120-1131.
10. Frank A.E. TRAIL and cancer therapy. Cancer Lett 2008, 263:14-25.
11. Wu X.X., Kakehi Y., Mizutani Y., Kamoto T., Kinoshita H., Isogawa Y., et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002, 20:949-954.
12. Kanzawa F., Akiyama Y., Saijo N., Nishio K. In vitro effects of combinations of cis- amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer 2003, 40:325-332.
13. Ma C., Niu X., Luo J., Shao Z., Shen K. combined effects of lapatinib and bortzomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity ofbortezomib against lapatinib-resistant breast cancer cells. Cancer Sci 2010, 101:2220-2226.
14. Fang J., Sawa T., Akaike T., Greish K., Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zincprotoporphyrin. Int J Cancer 2004, 109:1-8.
15. Khandare J.J., Chandna P., Wang Y., Pozharov V.P., Minko T. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther 2006, 317:929-937.
16. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
17. Lee J.H., Engler J.A., Collawn J.F., Moore B.A. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 2001, 268:2004-2012.
18. Oh S., Kim B.J., Singh N.P., Lai H., Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 2009, 27:33-39.
19. Boado R.J. RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx 2005, 2:139-150.
20. Rainov N.G., Gorbatyuk K., Heidecke V. Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 2008, 3:2-9.
21. Frérart F., Sonveaux P., Rath G., Smoos A., Meqor A., Charlier N., et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizingstrategy. Clin Cancer Res 2008, 14:2768-2774.
22. Sun Q., Cai S., Peterson B.R. Selective disruption of early/recycling endosomes: release of disulfide-linked cargo mediated by a N- alkyl-3beta-cholesterylamine capped peptide. J Am Chem Soc 2008, 130:10064-10065.
23. Ulbrich K., Etrych T., Chytil P., Jelínková M., Ríhová B. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release 2003, 87:33-47.
24. Kono K., Kojima C., Hayashi N., Nishisaka E., Kiura K., Watarai S., et al. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials 2008, 29:1664-1675.
25. Banerjee S.S., Chen D.H. Multifunctional pH-sensitive magnetic nanoparticles for simultaneous imaging, sensing and targeted intracellular anticancer drug delivery. Nanotechnology 2008, 19:505104.
26. Etrych T., Jelinkova M., Rihova B., Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 2001, 73:89-102.
27. Han L., Li J., Huang S., Huang R., Liu S., Hu X., et al. Peptide-conjugated polymidoamine dendrimer as a nanoscaled tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011, 32:2989-2998.
28. Han L., Huang R., Li J., Liu S., Huang S., Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011, 3:1242-1252.
29. Han L., Huang R., Liu S., Huang S., Jiang C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharmacol 2010, 7:2156-2165.
30. Huang R., Liu S., Shao K., Han L., Ke W., Liu Y., et al. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene deliveryvectors. Nanotechnology 2010, 21:265101.
31. Hermann T.W., Yen W.C., Tooker P., Fan B., Roegner K., Negro-Vilar A., et al. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 2005, 50:9-18.
32. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612.
33. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008, 69:1-9.
34. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
35. Heming T.A., Tuazon D.M., Davé S.K., Chopra A.K., Peterson J.W., Bidani A. Post-transcriptional effects of extracellular pH on tumor necrosis factor-alpha production in RAW 246.7 and J774 A.1 cells. Clin Sci (Lond) 2001, 100:259-266.
36. Engin K., Leeper D.B., Cater J.R., Thistlethwaite A.J., Tupchong L., McFarlane J.D. Extracellular pH distribution in human tumours. Int J Hyperthermia 1995, 11:211-216.
37. Marion M.F. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003, 139:89-97.
38. Huang Y., Sheikh M.S. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007, 224:284-289.
39. Gen S.W. TRAIL as a target in anti-cancer therapy. Cancer Lett 2009, 285:1-5.
40. Aroui S., Brahim S., Hamelin J., De Waard M., Bréard J., Kenani A. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis 2009, 14:1352-1365.
41. Abou El Hassan M.A., van der Meulen-Muileman I., Abbas S., Kruyt F.A. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 2004, 78:12243-12251.
42. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283.
43. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., et al. Reversal of multidrug resistanceby transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 2007, 10:350-357.
44. Wang G.Q., Gastman B.R., Wieckowski E., Goldstein L.A., Gambotto A., Kim T.H., et al. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 2001, 276:34307-34317.
45. Panaretakis T., Pokrovskaja K., Shoshan M.C., Grandér D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002, 277:44317-44326.
46. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24:1759-1763.